Navigation Links
Caution on stem cell therapy
Date:6/8/2008

SALT LAKE CITY A single organ may contain more than one type of adult stem cell a discovery that complicates prospects for using the versatile cells to replace damaged tissue as a treatment for disease, according to a new study from the laboratory of geneticist Mario Capecchi, the University of Utah's Nobel Laureate.

In the June 8 online issue of the journal Nature Genetics, Capecchi and geneticist Eugenio Sangiorgi report that when they used a gene named Bmi1 to mark the presence of adult stem cells in the intestines of mice, they were surprised to find the specific cells mostly in the upper third of the mouse intestine.

That indicates at least one or two other types of adult stem cells must exist to maintain and repair the middle and lower thirds of the mouse's guts. The small intestine in a mouse is almost 12 inches long if stretched from end to end.

Adult stem cells are "undifferentiated" cells that can become any type of cell in the organ in which they are found. Medical researchers hope to transplant adult stem cells to treat various diseases. Examples include placing adult stem cells in the pancreas to replace damaged insulin-producing cells, in the heart to replace cardiac muscle cells killed by heart attack, and in the brain to replace dopamine-producing cells damaged in Parkinson's disease patients.

The new discovery "is important because people are talking about stem cell therapy; they want to stick in stem cells to treat disease," says Capecchi, a winner of the 2007 Nobel Prize in Physiology or Medicine.

"People always thought about a uniform stem cell population in each organ, but now we are saying there are multiple stem cell populations in a given organ, so if you're going to do therapy, you have to recognize this complexity," adds Capecchi, co-chair and distinguished professor of human genetics at the University of Utah and an investigator with the Howard Hughes Medical Institute.

Sangiorgi, a postdoctoral fellow in human genetics, adds: "There are probably different stem cells in the small intestine doing different things."

If more than one kind of adult stem cell is required to generate the intestinal lining, "it wouldn't be surprising to see it is true for other organs as well," Capecchi says.

Adult stem cells have been seen as an alternative to embryonic stem cells, which are able to become any kind of cell in the body not just in a given organ and are obtained from test-tube fertilization of eggs left over by couples attempting to have babies. Embryonic stem cells have been controversial because abortion foes consider them to be human beings rather than a small batch of cells.

Capecchi won the Nobel with Sir Martin Evans and Oliver Smithies for developing gene targeting, a method of using embryonic stem cells to "knock out" genes in mice, then observing what goes wrong to determine any gene's normal function.

Getting to the Guts of Adult Stem Cells

Stem cells in the intestine are among the best studied. They are required to produce new cells for the intestinal lining as older ones wear out every two to five days.

"It's a hell of an environment," Capecchi says. "Food is being thrown in there, and enzymes to break down that food. This is a way of maintaining the intestine intact."

The intestinal adult stem cells give rise to various cells in the small intestine: cells to absorb foods; cells to secrete mucus that make the lining smooth and protect it; cells involved in protecting the organism against bacteria and other disease organisms; and cells that produce substances involved in communication among cells.

But researchers have had trouble identifying the stem cells so they can be studied.

"Adult stem cells are a giant black box," Sangiorgi says.

Hijacking a Gene to Unveil Stem Cells

Dutch researchers recently found a "marker" named Lgr5 to label intestinal stem cells. Sangiorgi and Capecchi used a similar method but a different "marker" a gene name Bmi1 which is "expressed" or activated in adult stem cells in the intestinal lining.

Labeling stem cells containing the Bmi1 gene involved tamoxifen, a drug used to treat and prevent breast cancer. Tamoxifen was used to activate an enzyme in cells that contain the Bmi1 gene so that the cells appeared blue when viewed under a microscope.

"We decided to hijack this gene to identify and label adult stem cells in the mouse intestine," Sangiorgi says.

Sangiorgi and Capecchi showed the cells they labeled with Bmi1 indeed were adult intestinal stem cells because they had two key properties: they self-renewed, or made more copies of themselves, and they gave rise to multiple kinds of other cells.

The stem cells, labeled blue, become various intestinal cells that are replaced about every five days. Yet the blue color was seen in intestinal tissue a year later, showing the stem cells within the tissue were renewing themselves, dividing and making new adult stem cells.

The geneticists also looked at the various kinds of intestinal-lining cells that arose from adult stem cells. All of them carried the blue tag, showing they originated from the adult stem cells.

When the geneticists used diphtheria toxin to kill the intestinal adult stem cells, "we wiped out the small intestine," says Capecchi. "Adult mice die within two days. That shows these stem cells are important for making the intestine."

Sangiorgi says the big surprise, however, was that the blue-dyed adult stem cells only appeared in normal concentrations in the upper third of the mouse, growing progressively fewer in number farther down the intestine, suggesting other kinds of adult stem cells must play the key role maintaining the middle and lower intestine.

Other Discoveries about Adult Stem Cells:

  • Sangiorgi and Capecchi took beta catenin a gene product often found in colon and digestive cancers and activated it in adult stem cells from the intestinal lining. "Tumors developed very rapidly," Capecchi says. "That suggests the stem cells are important in the formation of cancer." There has been debate over the extent to which cancer originates from stem cells versus the cells that are their progeny. Sangiorgi says: "Is cancer derived from stem cells or not? In some cases it is, in some cases it is not."

  • The geneticists found that the adult stem cells marked with the Bmi1 gene differed from the Dutch researchers' adult stem cells, marked with the Lgr5 gene. The difference was their location within crypts, which are small pits in the intestine's lining. Stem cells divide in crypts, producing progenitor cells that become intestinal cells.

There has been debate over where adult intestinal stem cells are found. The Utah geneticists found their Bmi1-marked adult stem cells dividing slowly near the top of the tube-like crypt, where it bubbles out to meet the intestine. The Dutch researchers found their Lgr5-marked cells dividing more rapidly farther down in the crypt, intermingled among "Paneth" cells, which produce enzymes to kill bacteria.

Capecchi sees no contradiction: "We both may be right. We may be looking at different phases of stem cells' life history," with the Bmi1-marked cells at an earlier phase and the cells marked by the other gene in a later phase.

"That says stem cell biology may be more complicated than we think, and they may be able to go from one state to another," and also migrating within crypts, he says. "They are still stem cells but are at different phases of their life cycle."


'/>"/>

Contact: Lee Siegel
leesiegel@ucomm.utah.edu
801-581-8993
University of Utah Health Sciences
Source:Eurekalert  

Related biology news :

1. Research cautions to catch-and-release in less than 4 minutes
2. A new radiation therapy treatment developed for head and neck cancer patients
3. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
4. UC health news: molecular pathway may predict chemotherapy effectiveness
5. MIT works toward safer gene therapy
6. Intravenous gene therapy protects normal tissue of mice during whole-body radiation
7. Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
8. Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases
9. Safe and effective therapy discovered for patients with protein-losing enteropathy
10. Ireland Cancer Center researchers advance stem cell gene therapy
11. Dolphin therapy a dangerous fad, Emory researchers warn
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Caution on stem cell therapy
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/21/2016)... Massachusetts , March 22, 2016 ... facial recognition with passcodes for superior security   ... ), a leading provider of secure digital communications services, ... their biometric technology and offer enterprise customers, particularly those ... secure facial recognition and voice authentication within a mobile ...
(Date:3/14/2016)... March 14, 2016 NXTD ) ("NXT-ID" ... commerce market, announces the airing of a new series of ... week of March 21 st .  The commercials will air ... popular Squawk on the Street show. --> NXTD ... growing mobile commerce market, announces the airing of a new ...
Breaking Biology News(10 mins):
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... ... That Will Drive Precision Farming in 2017 and Beyond. The paper outlines the ... in the precision ag industry. , “We’ve witnessed a lot of highs and ...
(Date:5/23/2016)... Palo Alto, CA (PRWEB) , ... May 23, ... ... tank and public interest organization focused on molecular nanotechnology, announced the winners for ... honor of pioneer physicist Richard Feynman, are given in two categories, one for ...
(Date:5/20/2016)... , ... May 20, 2016 , ... The recent recall ... as reported by Food Safety News on May 12, 2016(1), demonstrates the need for ... Olsen, CEO of Baltimore-based biotech firm, PathSensors, Inc. , PathSensor’s latest ...
(Date:5/19/2016)... Regen BioPharma, Inc ... announced today initiation of a preclinical development program ... cancer immunotherapeutic product leveraging its NR2F6 immunological checkpoint. ... generation of cord blood derived killer cells whose ... product in development will be a "universal donor" ...
Breaking Biology Technology: